GSK's Blenrep, withdrawn due to trial failure, showed promising results when combined with PomDex for relapsed multiple myeloma patients.
GSK's Blenrep, a blood cancer drug withdrawn due to trial failure, has shown promising results when combined with another cancer treatment, PomDex. Study data presented at the American Society of Clinical Oncology conference revealed that Blenrep nearly halved relapsed multiple myeloma patients' risk of disease progression or death. Patients taking the drug combination did not experience disease progression at 21.8 months, while those not on the treatment saw their disease advance at 12.7 months.
June 02, 2024
8 Articles